New pharmacological therapies to slow the progression of diabetic kidney disease
e-seminar #3
Mineralocorticoid receptor (MR) antagonist in diabetes kidney disease: results from FIDELIO-DKD study
Speaker: Rajiv Agarwal, USA
External Panellists:
Michael Burnier, CH
Peter Rossing, DK
Maria Soler, ES
Annette Bruchfeld, SWE
Moderated by Kate Stevens, UK
Thursday January 21, 2021 at 5 PM CET
New York 11 AM / San Francisco 8 AM / Buenos Aires 12 AM / Rio de Janeiro 10 AM / Moscow 6 PM / New Delhi 8.30 PM / Jakarta 10 PM / Beijing 11 PM / Sydney Friday 1 AM
New pharmacological therapies to slow the progression of diabetic kidney disease
e-seminar #2
New guidelines to optimize the clinical care of people with diabetes and CKD
Panellists
Speaker: Ian De Boer, USA
External Panellist: Katherine Tuttle, USA
Moderated by Christoph Wanner, D
Thursday January 14, 2021 at 4 PM CET
New York 10 AM / San Francisco 7 AM / Buenos Aires 11 AM / Rio de Janeiro 9 AM / Moscow 5 PM / New Delhi 7.30 PM / Jakarta 9 PM / Beijing 10 PM / Sydney Friday 12 AM
New pharmacological therapies to slow the progression of diabetic kidney disease
e-seminar #1
SGLT2- inhibitors and CKD patients: drugs for everyone?
Panellists
Christoph Wanner, Nephrologist, D
Hiddo J.L. Heerspink, Clinical Pharmacologist, NL
Gert Mayer, Nephrologist, A
Moderated by Kate Stevens, Nephrologist, UK
Please send questions to education@era-edta.org
Thursday October 15, 2020 at 4 PM BST/5 PM CEST
New York 11 AM / San Francisco 8 AM / Buenos Aires 12 AM / Rio de Janeiro 10 AM / Moscow 6 PM / New Delhi 8.30 PM / Jakarta 10 PM / Beijing 11 PM / Sydney Friday 1 AM
ERA-EDTA is organizing a series of e-seminars to initiate an open discussion, among the nephrology community, on how the results obtained in the recent trials can be applied to the needs of patients. During these e-seminars, every attendee will learn more about the study’s protocols and results, type of populations studied and parameters followed. There will also be educational elements about the magnitude of the effects in order to provide to the nephrology community a clearer understanding of the benefit and the risk of these, relatively new, classes of drugs.
